Contrast Media Injectors Market Report 2025

The contrast media injectors market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.79 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased incidence of chronic diseases, increased diagnostic imaging procedures, demand for minimally invasive procedures, expansion of healthcare infrastructure, growing aging population.

The contrast media injectors market size is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to rise in interventional radiology procedures, increasing prevalence of cancer, focus on patient safety and comfort, globalization of healthcare services, regulatory support and compliance. Major trends in the forecast period include automation and connectivity, emergence of dual-head injectors, advancements in injector technology, focus on patient safety, rise in interventional radiology procedures, enhanced imaging techniques and modalities.

The anticipated growth of the contrast media injectors market is set to be propelled by the increasing incidence of cancer and cardiovascular diseases (CVD). Cancer, characterized by uncontrolled cell growth and dissemination, and CVD, impacting the heart or blood vessels, are driving factors for the market. Contrast media injectors play a crucial role in diagnostic imaging, enhancing image quality, ensuring patient safety, and improving blood flow and tissue perfusion. Notably, statistics from the American Cancer Society reveal a 3.16% growth in cancer cases from 1,898,160 in 2021 to 1,958,310 in January 2023. Additionally, the World Heart Federation reports that over 500 million individuals globally will be affected by cardiovascular diseases in April 2023, leading to 20.5 million fatalities in 2021, constituting nearly one-third of total global mortality. This surge in cancer and CVD cases is a significant driver for the contrast media injectors market.

The increasing demand for non-invasive diagnostic procedures is anticipated to drive the growth of the contrast media injectors market in the future. Non-invasive diagnostic procedures are medical examinations or treatments that do not require physical entry into the body through natural or artificial openings or involve skin penetration. Contrast media injectors play a crucial role in non-invasive diagnostic methods, particularly in imaging techniques such as computed tomography (CT) scans and magnetic resonance imaging (MRI). For example, in May 2023, the National Health Service (NHS) England reported that in January 2023, plain radiography (X-ray) was the most frequently used imaging technique, with 1.65 million procedures performed. This was followed by diagnostic ultrasonography (Ultrasound) at 0.81 million, computerized axial tomography (CT scan) at 0.52 million, and magnetic resonance imaging (MRI) at 0.31 million. Therefore, the growing demand for non-invasive diagnostic procedures is propelling the growth of the contrast media injectors market.

Strategic partnerships are emerging as a prominent trend within the contrast media injectors market. Major companies in this sector are actively engaging in collaborations to foster new relationships, particularly those involving similar product developments. An illustrative example is the collaboration between Qaelum NV, a Belgium-based provider of advanced dose and contrast management software solutions, and Ulrich GmbH & Company KG, a France-based surgical instruments manufacturer and distributor. By pooling their resources, these companies aim to integrate Qaelum NV's advanced contrast management solution with Ulrich Medical's contrast media injectors, thereby addressing the requirements of hospitals and imaging networks. This partnership model demonstrates the industry's commitment to enhancing collaborative efforts for mutual benefit.

Key players in the contrast media injector market are directing their efforts towards the development of innovative products, such as generic contrast media injectables. These pharmaceutical products, containing contrast agents, play a pivotal role in enhancing visibility during medical imaging procedures such as CT scans and MRIs. Notably, Fresenius Kabi, a Germany-based pharmaceutical company, introduced two novel drugs in August 2023. The first, Gadobutrol Injection, is a gadolinium-based contrast agent tailored for MRI use, expanding Fresenius Kabi's radiology portfolio. The second, Plerixafor Injection, serves as a hematopoietic stem cell mobilizer, complementing the company's extensive collection of generic injectable oncology medicines. This strategic focus on product innovation underscores the industry's commitment to gaining a competitive edge and broadening its customer base.

In November 2022, GE HealthCare Technologies Inc., a prominent US-based manufacturing company, entered into a partnership with Ulrich GmbH & Co. KG. The primary objective of this collaboration is to introduce multi-dose contrast media injectors in the U.S. market and bolster the sales of CT motion injectors. Ulrich GmbH & Co. KG., based in France, specializes in the development, production, and distribution of spinal systems and contrast medium injectors. This collaboration exemplifies GE HealthCare Technologies Inc.'s strategic approach to expanding its market presence and leveraging the expertise of partners to enhance its product offerings, particularly in the realm of contrast media injectors.

Major companies operating in the contrast media injectors market include The Bracco Group, Bayer AG, Medtron AG, Ulrich GmbH And Co. KG, General Electric Company, Nemoto Kyorindo Co. Ltd., Guerbet Group, Sino Medical-Device Technology Co. Ltd, Apollo RT Co.Ltd, Shenzhen Anke High-tech Co. Ltd, Vivid Imaging, AngioDynamics. Inc., Medrad Inc., TaeWoong Medical Co. Ltd., Medtronic Plc, ACIST Medical Systems, Boston Scientific Corporation, Mallinckrodt Pharmaceuticals, Lantheus Medical Imaging Inc., Imaxeon Pty Ltd.

North America was the largest region in the contrast media injectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global contrast media injectors market report during the forecast period. The regions covered in the contrast media injectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the contrast media injectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Contrast media injectors are advanced medical devices designed for administering contrast media to enhance tissue visibility in medical imaging procedures, ensuring superior accuracy and precision for optimal surgical outcomes.

The primary offerings in the contrast media injectors market include consumables, injector systems, and accessories. Consumables, also known as medical injectors, play a pivotal role in safeguarding against breaks or leaks that could lead to potential harm, injector downtime, or other undesirable incidents. These injectors are integral for conducting safe and consumable imaging procedures in diagnostics. The market features various types of injectors, including single head injectors, dual-head injectors, and syringeless injectors, tailored for applications in radiology, interventional cardiology, and interventional radiology. They find widespread usage in hospitals, diagnostics centers, and ambulatory surgery centers, catering to the diverse needs of medical professionals and contributing to the advancement of imaging precision and diagnostic capabilities.

The contrast media injectors market research report is one of a series of new reports that provides contrast media injectors market statistics, including contrast media injectors industry global market size, regional shares, competitors with a contrast media injectors market share, detailed contrast media injectors market segments, market trends and opportunities, and any further data you may need to thrive in the contrast media injectors industry. This contrast media injectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The contrast media injectors market consists of sales of empower CTA+, hydraulic-powered MR injectors, computed tomography (CT) injectors, and syringe devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.